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Abstract
Background: In human, respiratory distress of the neonates, which occurs in prematurity, is
prevalent in male. Late in gestation, maturation of type II pneumonocytes, and consequently the
surge of surfactant synthesis are delayed in male fetuses compared with female fetuses. Although
the presence of higher levels of androgens in male fetuses is thought to explain this sex difference,
the identity of genes involved in lung maturation that are differentially modulated according to fetal
sex is unknown. We have studied the sex difference in developing mouse lung by gene profiling
during a three-day gestational window preceding and including the emergence of mature PTII cells
(the surge of surfactant synthesis in the mouse occurs on GD 17.5).
Methods: Total RNA was extracted from lungs of male and female fetal mice (gestation days 15.5,
16.5, and 17.5), converted to cRNA, labeled with biotin, and hybridized to oligonucleotide
microarrays (Affymetrix MOE430A). Analysis of data was performed using MAS5.0, LFCM and
Genesis softwares.
Results: Many genes involved in lung maturation were expressed with no sex difference. Of the
approximative 14 000 transcripts covered by the arrays, only 83 genes presented a sex difference
at one or more time points between GDs 15.5 and 17.5. They include genes involved in hormone
metabolism and regulation (i.e. steroidogenesis pathways), apoptosis, signal transduction,
transcriptional regulation, and lipid metabolism with four apolipoprotein genes. Genes involved in
immune functions and other metabolisms also displayed a sex difference.
Conclusion: Among these sexually dimorphic genes, some may be candidates for a role in lung
maturation. Indeed, on GD 17.5, the sex difference in surfactant lipids correlates with the sex
difference in pulmonary expression of apolipoprotein genes, which are involved in lipid transport.
This suggests a role for these genes in the surge of surfactant synthesis. Our results would help to
identify novel genes involved in the physiopathology of the respiratory distress of the neonates.
Background
Hyaline membrane disease (respiratory distress of the
neonate) occurs primarily in premature infants. A major
cause of this disease is surfactant deficiency. Hyaline
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membrane disease and surfactant synthesis are both
affected by fetal sex. Indeed, the surge of surfactant syn-
thesis is normally delayed in the developing male lung
when compared with the female, while hyaline mem-
brane disease is prevalent in males [1-5].
Surfactant synthesis occurs in type II pneumonocytes
(PTII) following maturation of these cells, which is pro-
moted by fibroblast-PTII cell communication [5]. This
maturation process is stimulated by glucocorticoids [6]
and involves some cytokines including epidermal growth
factor (EGF) [7,8], neuregulin-1 [9], and keratinocyte
growth factor (KGF) [10] as positive regulators and trans-
forming growth factor-β1 (TGF-β1) [11-14] as negative
regulator.
Androgens have been shown to both delay fetal lung mat-
uration in vivo [3,15] and block the stimulatory effect of
corticosteroids on surfactant synthesis in vitro [16]. These
effects are mediated through binding of androgens to
androgen receptors [3,15,17], which are present in both
male and female lung tissues [18,19]. There is an active
androgen metabolism in the developing lung where
androgen synthesis [18,20] and inactivation [18,21]
occur. In mice, many genes involved in androgen metab-
olism are regulated specifically on gestation day (GD)
17.5 in parallel with the emergence of mature PTII cells
([18] and unpublished data).
The surge of surfactant synthesis occurs on GD 17.5 in the
mouse [3,18] with a sex difference in pulmonary sur-
factant lipid levels [3]. Male mice carrying the Tfm gene
(male with testicular feminization), which have no func-
tional androgen receptors, have surfactant levels compara-
ble with those of normal females at a comparable
developmental time point [3]. Therefore, the mouse is a
good model to study the effect of fetal sex on the timing
of the developmental events related to the surge of sur-
factant synthesis.
Knowing that the surge of surfactant synthesis is delayed
in male fetal mouse lungs compared with females, we
were interested to identify genes that are expressed with a
sex difference during the gestational period that overlaps
the surge of surfactant production. We found, by microar-
ray analysis, genes exhibiting a sex difference in expres-
sion in lung development during a three-day window
preceding and including the emergence of mature PTII
cells. To date, no gene profiling study of sex differences in
the embryonic lung tissue exists. Using Affymetrix tech-
nology, we have studied about 14,000 transcripts and var-
iants with more than 22,600 probe sets in male and
female fetal lungs on GDs 15.5, 16.5, and 17.5.
Methods
Animals
Protocols were approved by the animal care and use com-
mittee and the institutional review board of the Centre de
Recherche du Centre Hospitalier Universitaire de Québec
(protocol 2002-080). Balb/C mice (Mus musculus) were
mated during the night. Appearance of the copulatory
plug was considered as gestation day 0.5 (GD 0.5). Preg-
nant females were euthanized by exposure to CO2. Fetal
sex was determined by examination of the genital tract
with a dissecting microscope at 15 × magnification. Fetal
lungs were collected and one pool of tissues was prepared
for each sex and each pregnant animal prior RNA extrac-
tion.
RNA extraction
Total RNA was extracted using Tri-reagent, a mixture of
phenol and guanidine thiocyanate in a monophasic solu-
tion (Molecular Research Center, Cincinnati, OH) as
described previously [22]. Each RNA sample was purified
on a CsCl gradient as described [23], using a TLA 120.2
rotor in an Optima MAX centrifuge (Beckman, Missis-
sauga, ON, Canada).
Preparation of probes
Samples were processed following the Small Sample Labe-
ling Protocol version II from Affymetrix [24]. This proto-
col is based on the principle of performing two cycles of
cDNA synthesis and in vitro transcription reactions for tar-
get amplification. Briefly, 10 µg of total RNA were con-
verted to cDNA by incubation with 400 units of
SuperScript II reverse transcriptase (Invitrogen, Carlsbad,
CA), a T7 oligonucleotide-d(T)24  as a primer (5'-
GGCCAGTGAATTGTAATACGACTCACTATAGGGAG-
GCGG(T)24-3'), combined with 1 mM dNTPs (deoxynu-
cleotide triphosphates) in 1 × first strand buffer (50 mM
Tris HCl pH 8.3, 75 mM KCl, 3 mM MgCl2, 10 mM DTT)
at 42°C for 1 h. Second strand cDNA synthesis was per-
formed using 40 units of DNA polymerase I (Invitrogen),
10 units of E. coli DNA ligase (Invitrogen), 2 units of
RNase H (Invitrogen), and 0.2 mM dNTPs in 1 × reaction
buffer (18.8 mM Tris-HCl pH 8.3, 90.6 mM KCl, 4.6 mM
MgCl2, 3.8 mM DTT, 0.15 mM NAD, 10 mM (NH4)2SO4)
at 16°C for 2 h. Each cDNA sample was blunt ended by
addition of 10 units of T4 polynucleotide kinase (Invitro-
gen) and incubation at 16°C for 10 min. cDNA samples
were purified by phenol-chloroform extraction using
phase lock gels (Brinkmann Instruments Inc., Missis-
sauga, ON, Canada), ethanol precipitated and resus-
pended in 10 µl of DEPC- (diethylpyrocarbonate) treated
H2O. First cycle amplification was performed using a
MEGAscript T7 Kit (Ambion, Austin TX). The mixture (10
µl final volume) was incubated at 37°C for 5 h. cRNA was
purified using a RNeasy Mini Kit (Qiagen, Valencia, CA)
according to the protocol of the manufacturer. PurifiedReproductive Biology and Endocrinology 2006, 4:25 http://www.rbej.com/content/4/1/25
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cRNA was reverse-transcribed to cDNA for a second time
following the protocol used for the first cycle. For the sec-
ond amplification, a T7 BioArray High Yield RNA Tran-
script Labeling Kit (Enzo Diagnostics, Farmingdale, NY)
was used to produce biotinylated cRNA. The mixture (20
µl final volume) was incubated at 37°C for 5 h with gentle
mixing every 30 min. Labelled cRNA was purified using a
RNeasy Mini Kit (Qiagen) according to the protocol of the
manufacturer. Purified cRNA was fragmented into seg-
ments of 20–300 nucleotide length by incubation in a
fragmentation buffer (100 mM potassium acetate, 30 mM
magnesium acetate, 40 mM Tris-acetate pH 8.1) for 20
min at 94°C. The quality of cRNA amplification and
cRNA fragmentation was monitored by micro-capillary
electrophoresis (Bioanalyser 2100, Agilent Technologies,
Mississauga, ON, Canada).
Microarray hybridization, scanning, and analysis
Each preparation of cRNA probe was hybridized to two
GeneChip Mouse Genome 430 A arrays (Affymetrix,
Santa Clara, CA). Each microarray was pre-hybridized in 1
× hybridization buffer (0.1 mg/ml herring sperm DNA,
0.5 mg/ml acetylated BSA) at 45°C for 10 min under con-
stant rotation (60 rpm). Then, the buffer was replaced by
a mixture containing 15 µg of fragmented cRNA in 1 ×
hybridization buffer, and the following internal controls
from Affymetrix: 5 nM control oligonucleotide B2 and 1 ×
eukaryotic hybridization control (1.5 pM BioB, 5 pM BioC,
25 pM BioD and 100 pM cre). Samples were incubated at
45°C for 16 h under constant rotation. Microarrays were
processed using an Affymetrix GeneChip Fluidic Station
400 (protocol EukGE-WS2Av4). Staining was initiated
with streptavidin-conjugated phycoerythrin (SAPE), fol-
lowed by amplification using a biotinylated anti-strepta-
vidin antibody and by a second round of SAPE.
GeneChips were scanned using a GeneChip Scanner 3000
with autoloader (Affymetrix). Data acquisition and analy-
sis were performed using the Microarray Suite 5.0 software
(Affymetrix). Signal intensities for β-actin and GAPDH
genes were used as internal quality controls; their ratio of
fluorescence intensities for the 5' and 3' ends was <2. Dif-
ferentially expressed genes were determined using the
LFCM software [25]. Briefly, variable fold change limit
(LFC) decreasing with gene expression value was used to
select differentially expressed genes. The LFC equation is Y
= a + b/X, were X is the minimum gene expression inten-
sity from two arrays and Y is the fold change limit. The
parameters a and b were estimated from the distribution
of ratios calculated from replicated chips. The resulting
cut-off point, Y = 1.8 + 62.0/X, gave an approximately con-
stant rate of false positive modulated genes of 0.1%. All
the genes having a fold change above this curve were con-
sidered significantly modulated. Data were also analysed
with the Genesis 1.6.0 Beta1 software [26]. The MOE430A
microarray provides coverage of over 22,600 probe sets
corresponding to about 14,000 transcripts and variants.
The probe sets were selected from sequences derived from
GenBank, dbEST and RefSeq. The sequence clusters were
created from the UniGene database (Build 107, June
2002) and then refined by analysis and comparison with
the publicly available draft assembly of the mouse
genome from the Whitehead Institute Center for Genome
Research (MSCG, April 2002) (for more details see [24]).
Results
Pregnant Balb/C mice were sacrificed on GDs 15.5, 16.5,
and 17.5. Total RNA prepared from male and female fetal
lungs, from each litter, was pooled in order to obtain the
following six samples: GD 15.5 males; GD 15.5 females
(each from 2 litters); GD 16.5 males; GD 16.5 females
(each from 2 litters); GD 17.5 males; and GD 17.5 females
(each from 1 litter) (number of fetuses per RNA prepara-
tion were respectively of 6, 9, 7, 9, 2, and 4). Previously,
the litters corresponding to GDs 15.5 and 17.5 have
shown sex differences in expression for several genes
[18,27]. Microarray analysis was performed using six
probes prepared from these RNA samples and 12 Gene-
Chip Mouse Genome 430 A array (in duplicate). Values
obtained for each gene were compared between sexes for
each GD.
Validation of data
Internal controls assessing the validity and reproducibility
of the data were satisfied (see Methods). For each experi-
ment, Table 1 shows the number of probe sets detected (p-
value = 0.05 based on raw signals obtained for each probe
set). Of these, the number of associated known and
unknown transcripts was determined from analysis of
probe set IDs using NetAffx (Affymetrix) and Excel
(Microsoft) softwares. Expressed sequence tags (ESTs),
Riken sequences, and all other unknown transcripts
("hypothetical","similar to"...) were sorted into the cate-
gory named "Unknowns".
Sex determination of fetuses was confirmed by analysis of
several genes associated with the Y-chromosome. Specifi-
cally, Ddx3y (DEAD (Asp-Glu-Ala-Asp) box polypeptide
3, Y-linked) (Id. #56, Table 2), Jarid1d (jumonji, AT rich
interactive domain 1D (Rbp2 like)) (Id. #57), also called
Smcy, Eif2s3y (Y chromosome-encoded subunit of the
initiation of translation factor Eif2) (Id. #50) and Uty
(ubiquitously transcribed tetratricopeptide repeat gene, Y
chromosome) (Id. #65) were expressed, as expected,
exclusively in male samples for each GD studied (Table
2).
The expression patterns of surfactant associated protein C
(SP-C) obtained from microarray experiments (Figure 1A)
and real time PCR (Figure 1B) using the same RNA prep-Reproductive Biology and Endocrinology 2006, 4:25 http://www.rbej.com/content/4/1/25
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arations are presented. The reported increase in SP-C
mRNA was observed in both cases.
Several genes of interest exhibiting no sex difference in 
expression
Several genes involved in lung development and
expressed with no sex difference in our study are pre-
sented in Table 3. These genes encode members of the
fibroblast growth factor (FGF) [28] and the TGFβ [29]
gene families, their receptors, epidermal growth factor-
receptor (EGF-R) [30], insulin-like growth factor I (IGF-I)
[31] and members of the surfactant-associated protein
family [32].
Genes with sexually dimorphic expression
Genes with sexually dimorphic expression in mouse lungs
on GDs 15.5, 16.5, and 17.5 are presented in Table 2.
These genes are distributed according to an adaptation of
the functional categories defined by the Gene Ontology
Consortium [33]. Only 33 genes displayed a sex difference
on GD 16.5 compared with 62 and 38 on GD 15.5 and
17.5, respectively. Of these, similar numbers of genes
showed higher expression levels for each sex on GD 15.5,
while 21 of the 33 genes identified on GD 16.5, and 32 of
the 38 genes identified on GD 17.5 presented higher
expression in the female lung. Hierarchical clustering and
expression profile of these genes are presented in Figure 2.
Discussion
This study targeted elucidation of a sex difference in the
fetal lung during a three-day gestation period overlapping
PTII cell maturation. This sex difference results in more
concern for a poorer prognosis for respiratory distress in
premature male infants. The genes identified here, with a
sexually dimorphic expression during the gestation period
examined in the mouse, likely contain key genes involved
in PTII cell maturation. Further studies are essential to
identify and to characterize these key genes, as our data
indicate that PTII cell maturation is not the only aspect of
lung development affected by sex during this period of
gestation.
Relative levels of SP-C gene expression on GDs 15 Figure 1
Relative levels of SP-C gene expression on GDs 15.5, 
16.5 and 17.5 Relative levels of SP-C gene expression (± 
SD) on GDs 15.5, 16.5 and 17.5 obtained by microarray 
hybridization (A) and real-time PCR (B). RNAs correspond-
ing to samples "a" and "b" in panel B were pooled prior to 
preparation of probes used in panel A. "a" and "b" refer to 
different litters.
Table 1: Overview of the microarray data characteristics
GD15.5 GD16.5 GD17.5
MFMFMF
Detected 
probesets (% 
present)*
12955 (57,3%) 12988 (57,4%) 12660 (56%) 12455 (55%) 12234 (54,1%) 12808 (56,6%)
Known genes† 6490 6464 6466 6424 6321 6561
Unknown 
transcripts†
2406 2433 2030 2019 1965 2060
*- Number of probe sets detected (p-value ≤ 0.05) relative to the total number of probe sets on the array
†- When multiple probe sets are associated to the same transcript, only one is considered M, male; F, femaleReproductive Biology and Endocrinology 2006, 4:25 http://www.rbej.com/content/4/1/25
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Table 2: Differentially expressed genes in the lung according to sex at GDs 15.5, 16.5 and 17.5
Id* Accession 
number
Gene name† Fold changes‡
Symbol GD15.5 (62)§ GD16.5 (33) GD17.5 (38) Chr.
Apoptosis
#1 BI662863 Rho-associated 
coiled-coil 
forming kinase 
1
Rock1 2.25
#2 NM_011997 caspase 8 
associated 
protein 2
Casp8ap2 2.15 4 11.4 cM
Cell adhesion
#3 NM_009925 procollagen, 
type X, alpha 1
Col10a1 M 10 22.0 cM
#4 L20232 integrin binding 
sialoprotein
Ibsp M 5 56.0 cM
#5 NM_031163 procollagen, 
type II, alpha 1
Col2a1 2.96 F 15 54.5 cM
#6 NM_007729 procollagen, 
type XI, alpha 1
Col11a1 2.25 3 53.1 cM
#7 AK004383 procollagen, 
type IX, alpha 1
Col9a1 1.96 1 15.0 cM
#8 U08020 procollagen, 
type I, alpha 1
Col1a1 (1.77) 11 56.0 cM
Cell growth
#9 NM_008341 insulin-like 
growth factor 
binding protein 
1
Igfbp1 M 11 1.3 cM
Coagulation
#10 NM_008877 plasminogen Plg F F 17 7.3 cM
#11 AK011118 fibrinogen, B 
beta 
polypeptide
Fgb F F 3 48.2 cM
#12 NM_133862 fibrinogen, 
gamma 
polypeptide
Fgg (3.81) F 3 41.3 cM
#13 BC005467 fibrinogen, alpha 
polypeptide
Fga (3.10) F 3 44.8 cM
#14 NM_010168 coagulation 
factor II
F2 (2.67) 2 47.5 cM
Endopeptidase activity
#15 BC012874 serine (or 
cysteine) 
proteinase 
inhibitor, clade 
A, member 1a
Serpina1a F F 12 51.0 cM
#16 NM_007443 alpha 1 
microglobulin/
bikunin
Ambp F F 4 30.6 cM
#17 NM_010582 inter-alpha 
trypsin 
inhibitor, heavy 
chain 2
Itih2 F F 2 1.0 cM
#18 NM_008407 inter-alpha 
trypsin 
inhibitor, heavy 
chain 3
Itih3 F F
#29 NM_007618 serine (or 
cysteine) 
proteinase 
inhibitor, clade 
A, member 6
Serpina6 (2.66) F 12 51.0 cMReproductive Biology and Endocrinology 2006, 4:25 http://www.rbej.com/content/4/1/25
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#20 NM_019429 protease, 
serine, 16 
(thymus)
Prss16 (2.65) 13 10.0 cM
Erythroid-associated
#21 NM_013848 erythroblast 
membrane-
associated 
protein
Ermap F 4 57.0 cM
#22 AF069311 Rhesus blood 
group CE and D
Rhced F 4 65.7 cM
#23 NM_053149 hemogen Hemgn (3.29) F F
#24 NM_010635 Kruppel-like 
factor 1 
(erythroid)
Klf1 (3.01)
#25 NM_133245 erythroid 
associated 
factor
Eraf (2.38)
#26 NM_010369 glycophorin A Gypa (2.27) 8 36.0 cM
#27 AJ007909 erythroid 
differentiation 
regulator 1
Erdr1 (1.75)
Hormone metabolism/regulation
#28 NM_008293 hydroxysteroid 
dehydrogenase-
1, delta<5>-3-
beta
Hsd3b1 M 3 49.1 cM
#29 AV021656 aldo-keto 
reductase family 
1, member B7
Akr1b7 M 6 14.0 cM
#30 NM_009995 cytochrome 
P450, family 21, 
subfamily a, 
polypeptide 1
Cyp21a1 M
#31 AI195150 group specific 
component
Gc F F 5 44.0 cM
#32 BG141874 transthyretin Ttr (3.93) F F 18 7.0 cM
#33 NM_031192 renin 1 
structural
Ren1 3.67 F
#34 NM_007423 alpha 
fetoprotein
Afp (2.64) F 5 50.0 cM
#35 U63146 retinol binding 
protein 4, 
plasma
Rbp4 (1.89) (2.16) 19 38.0 cM
Immune functions
#36 NM_011558 T-cell receptor 
gamma, variable 
4
Tcrg-V4 F F F
#37 NM_009019 recombination 
activating gene 
1
Rag1 F F 2 56.0 cM
#38 M58149 CD3 antigen, 
gamma 
polypeptide
Cd3g F F 9 26.0 cM
#39 AF119253 histocompatibili
ty 2, class II 
antigen A, alpha
H2-Aa F
#40 AV058500 P lysozyme 
structural
Lzp-s 3.42 1.70
#41 X67128 T-cell receptor 
beta, variable 13
Tcrb-V13 (1.97) F F 6 20.5 cM
#42 BC011474 lymphocyte 
protein tyrosine 
kinase
Lck (2.87) 4 59.0 cM
#43 BC003476 Ia-associated 
invariant chain
Ii (2.10) 18 32.0 cM
Lipid metabolism
Table 2: Differentially expressed genes in the lung according to sex at GDs 15.5, 16.5 and 17.5 (Continued)Reproductive Biology and Endocrinology 2006, 4:25 http://www.rbej.com/content/4/1/25
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#44 NM_013475 apolipoprotein 
H
Apoh F F 11 63.0 cM
#45 NM_009692 apolipoprotein 
A-I
Apoa1 F F 9 27.0 cM
#46 NM_009695 apolipoprotein 
C-II
Apoc2 (3.20) F 7 4.0 cM
#47 NM_013474 apolipoprotein 
A-II
Apoa2 (2.27) F 1 92.6 cM
#48 BC002148 fatty acid 
binding protein 
4, adipocyte
Fabp4 2.33 3 13.9 cM
#49 BG922397 p47 protein p47 1.84
Protein biosynthesis
#50 NM_012011 eukaryotic 
translation 
initiation factor 
2, subunit 3, 
structural gene 
Y-linked
Eif2s3y M M M
#51 NM_009079 ribosomal 
protein L22
Rpl22 1.86
#52 AI642440 ribosomal 
protein S13
Rps13 (1.81)
Signal transduction
#53 X67702 secretoglobin, 
family 1A, 
member 1 
(uteroglobin)
Scgb1a1 M
#54 BF537798 receptor 
(calcitonin) 
activity 
modifying 
protein 2
Ramp2 2.07 2.16 11 61.5 cM
#55 NM_016721 IQ motif 
containing 
GTPase 
activating 
protein 1
Iqgap1 1.96 7 39.0 cM
Transcriptionnal regulation
#56 AA210261 DEAD (Asp-
Glu-Ala-Asp) 
box polypeptide 
3, Y-linked
Ddx3y M M M Y 2.07 cM
#57 AF127244 jumonji, AT rich 
interactive 
domain 1D 
(Rbp2 like)
Jarid1d M M M Y 2.03 cM
#58 AA617392 Max protein Max F 12 32.0 cM
#59 BB393998 flap structure 
specific 
endonuclease 1
Fen1 3.70 (2.96)
#60 NM_007496 AT motif 
binding factor 1
Atbf1 (2.16) 8 E1
Transport
#61 BC024643 albumin 1 Alb1 (2.71) (8.68) 5 50.0 cM
#62 AF440692 Transferring Trf (2.02) (3.29) 9 56.0 cM
#63 BB448377 solute carrier 
family 4 (anion 
exchanger), 
member 1
Slc4a1 (2.07) 11 62.0 cM
#64 NM_026331 mitochondrial 
solute carrier 
protein
Mscp (1.90)
Others
Table 2: Differentially expressed genes in the lung according to sex at GDs 15.5, 16.5 and 17.5 (Continued)Reproductive Biology and Endocrinology 2006, 4:25 http://www.rbej.com/content/4/1/25
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#65 BB742957 ubiquitously 
transcribed 
tetratricopeptid
e repeat gene, Y 
chr.
Uty M M M Y 2.06 cM
#66 AI256465 alpha-2-HS-
glycoprotein
Ahsg F F 16 15.0 cM
#67 AK003182 myosin, light 
polypeptide 1
Myl1 F 1 34.1 cM
#68 BG806300 inactive X 
specific 
transcripts
Xist (3.34) (13.22) (2.41) X 42.0 cM
#69 AV224521 Gelsolin Gsn 3.27 2 24.5 cM
#70 NM_025711 Asporin Aspn 2.72
#71 BC002136 coronin, actin 
binding protein 
1A
Coro1a (2.48) 7 62.5 cM
#72 AK017440 RNA imprinted 
and 
accumulated in 
nucleus
Rian (2.27) 12 54.5 cM
#73 AV156640 expressed in 
non-metastatic 
cells 1, protein
Nme1 2.23
#74 AF291655 Tenomodulin Tnmd 2.12
#75 BB745314 male-specific 
lethal-2 
homolog 
(Drosophila)
Msl2 (2.11)
#76 BB490338 calponin 3, 
acidic
Cnn3 2.04
#77 BB475271 LUC7-like 2 (S. 
cerevisiae)
Luc7l2 1.96
#78 NM_053123 SWI/SNF 
related, matrix 
associated, actin 
dependent 
regulator of 
chromatin, 
subfamily a, 
member 1
Smarca1 1.93
#79 BM207360 unc-50 homolog 
(C. elegans)
Unc50 1.91
#80 AV011848 malate 
dehydrogenase 
1, NAD 
(soluble)
Mdh1 1.89 11 12.0 cM
#81 AA270173 Lamin B1 Lmnb1 (1.89) 18 29.0 cM
#82 BB192717 protein 
phosphatase 2 
(formerly 2A), 
reg. subunit A 
(PR 65), alpha 
isoform
Ppp2r1a (1.88)
#83 BE372352 ARP3 actin-
related protein 
3 homolog 
(yeast)
Actr3 1.77
Unknowns
#84 AA717264 Transcribed 
sequences
2.51
#85 BC021831 CDNA clone 
MGC:67258 
IMAGE:641364
8, complete cds
(2.14) (2.36)
Table 2: Differentially expressed genes in the lung according to sex at GDs 15.5, 16.5 and 17.5 (Continued)Reproductive Biology and Endocrinology 2006, 4:25 http://www.rbej.com/content/4/1/25
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Analysis of the data has to be performed in the context of
lung development where a transient delay in the surge of
surfactant synthesis is observed. Therefore, as in the case
of the surge of surfactant synthesis, some genes can be
subject to a transient delay in expression for one sex. The
case of the Cyp21a1 gene clearly illustrates this occur-
rence. Recently, we showed that Cyp21a1, a gene involved
in corticosteroid synthesis, is expressed specifically on GD
15 in the fetal mouse lung [27]. Of the six litters studied
on GD 15.5 and obtained using the same mating window
of ± 8 hours, two litters presented high expression of
Cyp21a1 in females only, whereas one litter had high
expression of this gene only in male fetuses. The three
remaining litters did not show any elevated levels of
expression for this gene (Figure 3). The exact gestation
time at which the pregnant females were sacrificed varied
from litter to litter according to the time where the females
were mated during the mating window of ± 8h. Knowing
that Balb/C is an inbred strain, variations from litter to lit-
ter should represent the expression pattern of Cyp21a1
gene at different times on GD 15. Consequently, our
results strongly suggested that Cyp21a1 should present a
narrow peak of expression on GD 15 with a delay for one
sex [27]. In the present study, expression of Cyp21a1 (Id.
#30) was detected by gene profiling only in males on GD
15.5. Real-time PCR analysis of the two litters pooled to
prepare probes on GD15.5 revealed that Cyp21a1 was
expressed at high levels only in male lungs (one out of two
litters) (data not shown). Therefore, our microarray
results are compatible with our previous report [27]. In
this example, the fact that we detected expression only in
male fetuses by microarrays depended only on the litters
used. Therefore, for the analysis of our microarray results,
the identity of the sex where expression is higher com-
pared to the other sex has to be considered with caution.
Other animals, mated some hours before or after the preg-
nant females used in this study within the same mating
window, could show elevated expression levels for the
other sex, or even present no sex difference at all, as a con-
sequence of a delayed expression in one sex.
Recently, we reported that all the genes involved in corti-
costeroid synthesis from cholesterol in the mature adrenal
gland are transiently expressed in the developing mouse
lung on GD 15 [27]. Hsd3b1 (Id. #28) encodes the 3β-
hydroxysteroid dehydrogenase type 1 enzyme that is
involved in this cascade of reactions (pregnenolone →
progesterone) along with Cyp21a1 (Id. #30) (progester-
one → deoxycorticosterone) as mentioned already. Both
Table 3: Several genes involved in lung development and expressed with no sex difference
FGF signaling pathway TGF-beta signaling 
pathway
Surfactant associated 
proteins
Others
Spry Fgfbp1 Tgfb1 Sftpa Egfr
Fgf1 Fgfr1op2 Tgfb2 Sftpb Igf1
Fgf7 Fgfrap1 Tgfb3 Sftpc
Fgf13 Akr1b8 Tgfbr1 Sftpd
Fgf18 Fgfrl1 Tgfbr2
Fgfr1 Tgfbr3
Fgfr2
Fgfr3
Fgfr4
#86 AK018316 DNA segment, 
Chr 2, ERATO 
Doi 145, 
expressed
D2Ertd145e 2.31 2 31.0 cM
#87 BE865094 expressed 
sequence 
AI448196
AI448196 (2.14)
#88 BB151477 RIKEN cDNA 
2810468K05 
gene
2810468K05Rik 1.88
*- Identification numbers of genes found in this study. †- Genes are presented in only one functional category although some of them could have 
been placed in more than one category. ‡- Values with no bracket correspond to higher levels for males, while values in brackets correspond to 
higher levels for females. The letter M (Male) or F (Female) replace the fold change value when the gene was expressed in one sex only. §- The 
number of genes differentially expressed at each gestational day (GD) is indicated.
Table 2: Differentially expressed genes in the lung according to sex at GDs 15.5, 16.5 and 17.5 (Continued)Reproductive Biology and Endocrinology 2006, 4:25 http://www.rbej.com/content/4/1/25
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Hierarchical clustering and expression profile of differentially expressed genes Figure 2
Hierarchical clustering and expression profile of differentially expressed genes Hierarchical clustering and expres-
sion profile of genes presented in Table 2. The day of gestation is indicated at top. Accession numbers and gene symbols are 
presented. For each gene individually, each value was normalized by division with the root mean square calculated from the six 
values. As a consequence, the relative values obtained for one gene cannot be compared to those of other genes. Expression 
levels are presented from black (no expression) to yellow (high relative expression level). The clustering was generated using 
the Genesis 1.6.0 Beta1 software (agglomeration rule of average linkage and Euclidean measurement distance) [26]. M, male; F, 
female.Reproductive Biology and Endocrinology 2006, 4:25 http://www.rbej.com/content/4/1/25
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genes were also found by microarray analysis to be
expressed transiently on GD 15 with a sex difference.
Some other genes related to steroid hormone metabo-
lism/regulation are expressed also with a sex difference in
fetal mouse lungs. This is the case for Akr1b7 (Id. #29)
which showed a sex difference in expression on GD 15.5.
This gene encodes an aldose reductase-like protein whose
major function is detoxification of isocaproaldehyde gen-
erated by conversion of cholesterol to pregnenolone by
the enzyme P450scc [34], the latter also being expressed
on GD 15.5 in the mouse fetal lung [27]. Scgb1a1 gene
(Id. #53) is expressed also on GD 15.5 with a sex differ-
ence. This gene encodes the secretoglobin family 1 A
member 1, also called Clara cell secretory protein (CCSP),
which is required for the appearance of Clara cells secre-
tory granules and thus participates to the composition of
the epithelial lining fluid [35]. Scgb1a1 gene can be
induced by glucocorticoids [36] and CCSP can act as an
anti-inflammatory protein [37]. It was also shown to bind
progesterone [38]. Some other genes were not detected by
microarrays although they are known to be expressed with
a sex difference in lung development as evidenced by real-
time PCR. These genes include 17β-hydroxysteroid dehy-
drogenase (HSD) type 2 and type 5 [18] which are
expressed at low levels in the lung, probably below the
minimal threshold of sensitivity of the microarray tech-
nology.
Some genes involved in the metabolism of non-steroidal
hormones were also found to be expressed differentially
between genders. This is the case for Ttr (Id. #32), which
codes for transthyretin, a common plasma carrier protein
for thyroid hormones and vitamin A metabolites [39].
Interestingly, retinoids are important regulators of normal
epithelial cell differentiation and proliferation [40] and
are involved in lung development [41]. Ren1 (Id. #33)
encodes for renin 1 and presented a sex difference in
expression on GD 15.5. Genes of the renin-angiotensin
system are known to be expressed in the fetal lung and,
interestingly, angiotensin II can present mitogenic effects
on human lung fibroblasts through the activation of the
type 1 angiotensin II receptor [42]. In our study, Ace
(angiotensin II converting enzyme), Agtr1, and Agtr2
(angiotensin II receptor type 1 and type 2) are expressed
with no sex difference (data not shown).
Our results demonstrate that genes coding for apolipopro-
tein (apo) AI (Id. #45), apoAII (Id. #47), apoCII (Id. #46),
and apoH (Id. #44) are co-expressed in the developing
lung. To our knowledge, none of these genes has been
found expressed in the lung. All of these genes present a
sex difference in favor of females in the developing lung
on GD 15.5 and 17.5, with no detectable expression on
GD 16.5. As demonstrated by real-time PCR, 17βHSD
types 2 and 5 were also expressed on GDs 15.5 and 17.5
with a sex difference for the majority of litters, but not on
GD16.5 [18]. Our results suggest that the expression of
these four apolipoprotein genes in the developing lung is
under active modulation. 17β-HSD types 5 and 2 genes
are involved in androgen synthesis and inactivation,
respectively. Such a similar pattern of expression for these
apolipoproteins and 17β-HSD genes may suggest a com-
mon regulatory mechanism, or an effect of androgens on
Hypothesis concerning the expression profile ofsome differ- entially expressed genes Figure 3
Hypothesis concerning the expression profile ofsome 
differentially expressed genes Our previous results sug-
gest that Cyp21a1 is expressed at different precise gestation 
time on GD 15 for each gender [27] as shown in the present 
figure. This hypothesis would explain why the expression 
profile of Cyp21a1 on GD15.5 varied from litter to litter and 
presented one of the following patterns : 1) high expression 
in female fetal lungs only; 2) high expression in male fetal 
lungs only; or 3) no elevated expression in male and female 
fetal lungs. Because Balb/C is an inbred strain, the mating 
window of 16h would explain the variation between litters. 
Genes presenting such an expression profile cannot be stud-
ied by microarrays from a pool of many litters because the 
sex difference in expression could be lost.Reproductive Biology and Endocrinology 2006, 4:25 http://www.rbej.com/content/4/1/25
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expression of these apolipoprotein genes. Apolipopro-
teins are constituents of circulating lipoproteins. ApoCII is
an essential cofactor/activator of lipoprotein lipase (LPL)
[43,44] while apoH was shown to enhance LPL [45]. This
enzyme catalyses the hydrolysis of the triacylglycerol com-
ponent of circulating lipoproteins (chylomicrons and very
low density lipoproteins (VLDLs)). It was reported that
the presence and activity of LPL in the lung may be impor-
tant for surfactant production [46]. LPL expression was
detected with no sex difference. ApoAI [47] and apoAII
[48] are major protein components of high density lipo-
proteins (HDLs). ApoAI is a potent activator of leci-
thin:cholesterol acyltransferase (LCAT), an HDL-
associated enzyme playing a role in reverse cholesterol
transport. It is possible that the sex difference in expres-
sion of four apolipoprotein genes in the lung could
explain in part the sex difference in surfactant lipids
observed on GD 17.5; although such a role in the surge of
surfactant synthesis has never been suspected for these
genes before the present study. It is also noteworthy that
many genes involved in lipid metabolism were expressed
with no sex difference during each gestational day studied
(data not shown). For example, this is the case for genes
encoding for LDL receptor, LDL receptor-related protein
1, phospholipid transfer protein, and HMG-CoA-reduct-
ase (3-hydroxy-3-methylglutaryl-Coenzyme A reductase),
the latter being known to catalyze the rate-limiting step of
cholesterol synthesis.
Along with other pathways, fibroblast growth factors
(FGFs) and TGFβ signaling pathways have been shown to
be involved in many aspects of lung development. We
observed expression of many genes that belong to these
pathways (Table 3). However, in the present study, these
genes exhibit no sexually dimorphic expression. This is in
line with our previous study by real-time PCR that showed
expression of 5 genes involved in lung maturation on GDs
16.5 and 17.5 with no sex difference, namely, LIF, IGF-I,
KGF (FGF-7), EGF-R, and neuregulin-1 [18]. Although it
is possible that these genes could be expressed with a sex
difference within a time window not covered by our stud-
ies, it seems that the sex difference in PTII cell maturation
could rely on other genes.
Tissue remodeling and structure also seem subject to sex-
ual differences in gene expression. Indeed, two genes
involved in apoptosis, namely, Rock1 (Rho-associated
coiled-coil forming kinase 1) (Id. #1) and Casp8ap2 (cas-
pase 8 associated protein 2) (Id. #2) are differentially
expressed on GD 16.5 between genders, while many genes
involved in cell adhesion are expressed with a sex differ-
ence on GD 15.5. In addition, IGF signaling pathway has
been shown to be important in mouse lung development
where it is involved in regulation of cell proliferation and
differentiation [31,49,50]. Igfbp1 (Id. #9) presented a sex
difference in expression on GD 15.5, whereas Igfbp1 defi-
ciency was associated with massive hepatocyte apoptosis
[51].
In preparation for important immunological challenges
related to its function, the developing lung acquires many
elements associated with innate and adaptive immunity.
Our data suggest that modulation of several genes
involved in immune functions of the lung is subject to sex
differences. Indeed, the predominating functional cate-
gory of genes showing sexual dimorphism on GD 16.5
concerns "immune functions". It has been shown that
many signaling pathways involved in lung morphogene-
sis and immune responses are crosslinked [52]. These
include TTF-1, GATA6 and HNF-3β transcription factors;
and FGF- and NF-κ B-dependant signaling pathways.
However, we did not detect any sex difference in expres-
sion for these genes.
Conclusion
This study revealed that many genes are expressed with a
gender difference in the fetal lung. Although we focused
on a brief gestational period overlapping the surge of sur-
factant synthesis, our data demonstrates that PTII cell
maturation is not the only aspect of lung development
under the influence of fetal sex. We suggest that, among
the genes identified here, some are related to the transient
delay in lung maturation observed for males. This would
help identify novel genes involved in the physiopathology
of respiratory distress of the neonate.
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